Literature DB >> 8317

The noradrenergic cyclic AMP generating system in the limbic forebrain: pharmacological characterization in vitro and possible role of limbic noradrenergic mechanisms in the mode of action of antipsychotics.

J B Blumberg, J Vetulani, R J Stawarz, F Sulser.   

Abstract

The cyclic AMP generating system in slices of the rat limbic forebrain was investigated. In consists of: (u) A noradrenergic system which responds to norepinephrine (NE) and isoproterenol. Though the rise of the nucleotide elicited by isoproterenol is more rapid than that caused by NE, the maximal effect is less than half of that induced by NE; (2) an adenosine-dependent system. The noradrenergic cyclic AMP generating system in the limbic forebrain displays a number of properties of a central NE receptor: it develops supersensitivity to NE and isoproterenol following prolonged deprivation of NE at postsynaptic sites (chronic treatment with reserpine or chemosympathectomy with 6-hydroxydopamine). When noradrenergic terminals are protected from 6-hydroxydopamine by desmethylimipramine, the responses to NE are not enhanced. Responses to NE are blocked by both propranolol and phentolamine, while responses to isoproterenol are blocked by propranolol but not by phentolamine. The adenosine-dependent system does not develop supersensitivity after central chemosympathectomy and is not blocked by either alpha- or beta-antagonists. While not altering the basal level of the nucleotide, clinically effective antipsychotic drugs caused a dose-dependent inhibition of the limbic noradrenergic cyclic AMP response with clozapine and pimozide being particularly potent (IC50 0.06 and 0.08 muM, respectively). Antipsychotic drugs do, however, not affect cyclic AMP responses elicited by adenosine. The results are compatible with the view that the central NE receptor is closely related to or may be an integral part of an adenylate cyclase system and that its blockade in the limbic forebrain by antipsychotic drugs may contribute to their therapeutic action.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 8317     DOI: 10.1016/0014-2999(76)90043-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

1.  Modification of the noradrenergic cyclic AMP generating system in the rat limbic forebrain by amphetamine: role of its hydroxylated metabolites.

Authors:  P L Mobley; E Sanders-Bush; H E Smith; F Sulser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-04       Impact factor: 3.000

2.  Role of cyclic nucleotides in receptor mechanisms.

Authors:  J Vetulani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977       Impact factor: 3.000

3.  Structural and steric requirements for beta-phenethylamines as agonists of the noradrenergic cyclic AMP generating system in the rat limbic forebrain.

Authors:  S E Robinson; P L Mobley; H E Smith; F Sulser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-06       Impact factor: 3.000

4.  A possible common mechanism of action of antidepressant treatments: reduction in the sensitivity of the noradrenergic cyclic AMP gererating system in the rat limbic forebrain.

Authors:  J Vetulani; R J Stawarz; J V Dingell; F Sulser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-05       Impact factor: 3.000

5.  Behavioural and biochemical effects of chronic reduction of cerebral noradrenaline receptor stimulation.

Authors:  A Dolphin; M Christina; M C Sawaya; P Jenner; C D Marsden
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-09       Impact factor: 3.000

6.  Effect of clonidine on the noradrenergic cyclic AMP generating system in the limbic forebrain and on medial forebrain bundle self-stimulation behavior.

Authors:  J Vetulani; N J Leith; R J Stawarz; F Sulser
Journal:  Experientia       Date:  1977-11-15

7.  Enhancement of noradrenaline release from rat cerebral cortex by neuroleptic drugs.

Authors:  G Gross; H J Schümann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980       Impact factor: 3.000

8.  Differential effects of haloperidol and clozapine on attention.

Authors:  M Cheal
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 9.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

10.  Development of and recovery from subsensitivity of the noradrenergic cyclic AMP generating system in brain. Effect of amphetamine following inhibition of its aromatic hydroxylation by iprindole.

Authors:  D H Manier; D D Gillespie; F Sulser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-08       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.